| Title : Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease - Neumann_2021_BMC.Neurol_21_422 |
| Author(s) : Neumann S , Taylor J , Bamford A , Metcalfe C , Gaunt DM , Whone A , Steeds D , Emmett SR , Hollingworth W , Ben-Shlomo Y , Henderson EJ |
| Ref : BMC Neurol , 21 :422 , 2021 |
| Abstract : Neumann_2021_BMC.Neurol_21_422 |
| ESTHER : Neumann_2021_BMC.Neurol_21_422 |
| PubMedSearch : Neumann_2021_BMC.Neurol_21_422 |
| PubMedID: 34715821 |
Neumann S, Taylor J, Bamford A, Metcalfe C, Gaunt DM, Whone A, Steeds D, Emmett SR, Hollingworth W, Ben-Shlomo Y, Henderson EJ (2021)
Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease
BMC Neurol
21 :422
Neumann S, Taylor J, Bamford A, Metcalfe C, Gaunt DM, Whone A, Steeds D, Emmett SR, Hollingworth W, Ben-Shlomo Y, Henderson EJ (2021)
BMC Neurol
21 :422